Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Ashley E Davis"'
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0203293 (2018)
METHODS:Ninety-six-week costs for antiretroviral drugs, adverse event management, and HIV care for individuals initiating RAL, ATV/r, or DRV/r as first-line therapy for HIV-1 infection were estimated using an economic model. Efficacy and safety data
Externí odkaz:
https://doaj.org/article/19af58ce47ff4dde8e4740f4fd087353
Autor:
Ashley M. Shemery, Meredith Zendlo, Jesse Kowalski, Erin Gorrell, Scott Everett, Jacob G. Wagner, Ashley E. Davis, Lauren G. Koch, Steven L. Britton, Joram D. Mul, Colleen M. Novak
Publikováno v:
Temperature. :1-15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::679addac72fb7558d72d909c89022a5e
https://doi.org/10.1080/23328940.2023.2171669
https://doi.org/10.1080/23328940.2023.2171669
Autor:
Donal Bisanzio, Ashley E. Davis, Sandra E. Talbird, Thierry Van Effelterre, Laurent Metz, Maren Gaudig, Valérie Oriol Mathieu, Anita J. Brogan
Publikováno v:
Vaccine. 41:684-693
Nonpharmaceutical interventions (NPI) and ring vaccination (i.e., vaccination that primarily targets contacts and contacts of contacts of Ebola cases) are currently used to reduce the spread of Ebola during outbreaks. Because these measures are typic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55269d40f31ab1c6879f704799bd3c9
https://doi.org/10.1016/j.vaccine.2022.11.036
https://doi.org/10.1016/j.vaccine.2022.11.036
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 3, Pp 533-542 (2017)
Trivalent inactivated influenza vaccines (IIV3s) protect against 2 A strains and one B lineage; quadrivalent versions (IIV4s) protect against an additional B lineage. The objective was to assess projected health and economic outcomes associated with
Externí odkaz:
https://doaj.org/article/d2fd59cc55cb4e9198decb60433a73cc
Publikováno v:
PharmacoEconomics. 39:421-432
Ibalizumab-uiyk (ibalizumab) is a first-in-class, long-acting, postattachment HIV-1 inhibitor for adults with multidrug-resistant (MDR) HIV-1 infection. This analysis examines the cost-effectiveness and budget impact of ibalizumab treatment for this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f7ae44bd110f41d94dbbcf5ea9b2788
https://doi.org/10.1007/s40273-020-00992-6
https://doi.org/10.1007/s40273-020-00992-6
Publikováno v:
HIV Medicine. 20:668-680
OBJECTIVES Early treatment of HIV-1 infection at all CD4 levels has demonstrated clinical and public health benefits. This analysis examined the costs, health outcomes, and cost-effectiveness of increased HIV-1 screening and early treatment initiatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f495b2cba61fd69bf7d9b012295ec251
https://doi.org/10.1111/hiv.12788
https://doi.org/10.1111/hiv.12788
Autor:
Lauren G. Koch, Devanshi M. Mehta, Lisa A. Beltz, Mark E. Smyers, Ashley E. Davis, Colleen M. Novak, Steven L. Britton
Publikováno v:
Exp Physiol
New findings What is the central question of this study? How does intrinsic aerobic capacity impact weight loss with 50% daily caloric restriction and alternate-day fasting? What is the main finding and its importance? Intermittent fasting is effecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b02109b66e89f83248a3d3442232a3f9
https://pubmed.ncbi.nlm.nih.gov/34086376
https://pubmed.ncbi.nlm.nih.gov/34086376
Publikováno v:
PharmacoEconomics. 39(4)
Ibalizumab-uiyk (ibalizumab) is a first-in-class, long-acting, postattachment HIV-1 inhibitor for adults with multidrug-resistant (MDR) HIV-1 infection. This analysis examines the cost-effectiveness and budget impact of ibalizumab treatment for this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::430a85646faa6dfdbaa9a183d67deb6c
https://pubmed.ncbi.nlm.nih.gov/33532919
https://pubmed.ncbi.nlm.nih.gov/33532919
Publikováno v:
HIV Clinical Trials. 18:214-222
The AIDS Clinical Trial Group (ACTG) 5257 clinical trial showed that raltegravir (RAL) was superior to atazanavir/ritonavir (ATV/r) and darunavir/ritonavir (DRV/r), when used in combination with emtricitabine/tenofovir DF (FTC/TDF), in a 96-week comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c459bc5baaf4b232380f8a138e57c98
https://doi.org/10.1080/15284336.2017.1402144
https://doi.org/10.1080/15284336.2017.1402144
Autor:
Sandra E. Talbird, Mena Boules, Robin S. Turpin, Abigail M. Wojtowicz, Ashley E. Davis, Tao Fan, Jeanne Jiang, Claire E. Mellott
Publikováno v:
Gastroenterology. 160:S-262
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c041987fd04520e3359353293d8cff30
https://doi.org/10.1016/s0016-5085(21)01360-3
https://doi.org/10.1016/s0016-5085(21)01360-3